Leading neuromuscular conditions — such as ALS, SMA, Duchenne muscular dystrophy and myasthenia gravis — are benefiting from innovative therapies and increasing R&D investment. https://finance.yahoo.com/news/neuromuscular-disease-therapeutics-market-reach-152000966.html